Atul C. Pande
Independent DirectorDr. Atul C. Pande, M.D. is Member of Scientific Advisory Board of MMS Holdings Inc. Dr. Pande had been an Independent Director at Karuna Therapeutics, Inc. since June 2019 until March 2024 and served as its Member of Scientific Advisory Board until March 18, 2024 and also previously served as its Director from July 29, 2016 to March 15, 2019. He serves as an Independent Director at Immunovant, Inc. since October 2019 and as a member of Immunovant Sciences Ltd.’s board of directors since October 2019. Dr. Pande served as a Director of Karuna Pharmaceuticals Inc. since July 29, 2016 until March 19, 2019. Dr. Pande has been a Member of Scientific Advisory Board at Tal Medical Inc. since December 1, 2014. He serves as Member of Scientific Advisory Board at Cennerv Pharmaceuticals Ltd. He serves on the Scientific Advisory Board of Cennerv Pharma PTE LTD. He is a Member of Advisory Board at Datavant, Inc. Dr. Pande served as Senior Advisor at PureTech Health plc from July 8, 2016 to February 23, 2017. Dr. Pande has served as Chief Medical Officer of PureTech Health PLC, a science-driven healthcare company, since February 2018 and previously served as its Chief Medical Officer since February 2017. Dr. Pande had been the Chief Medical Officer and Executive Vice President of Tal Medical Inc from December 1, 2014 to December 2017. He serves as President and Chief Executive Officer of Verity BioConsulting LLC since April 2014. He served as Senior Vice President and Head of Neurosciences at GSK. He served as the Chief Medical Officer of Cenerx Biopharma, Inc. since December 13, 2005. He served as Senior Vice President and Senior Advisor of Pharmaceutical R&D at GlaxoSmithKline from 2007 to April 2014. He has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande's broad industry experience includes several years of developing new medicines at Eli Lilly, Parke-Davis. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury and Alzheimer's and Parkinson's diseases. He served as Vice President and Neurosciences Development Leader at Pfizer and responsible for the development and implementation of Pfizer''s overall neuroscience strategy including neurology, psychiatry and pain. He also served as Pfizer''s worldwide CNS Portfolio Leader, supervising one of the industry''s largest neuroscience programs. He led the development of the approved Lyrica, a new medicine for the treatment of neuropathic pain and epilepsy. He serves as a Director of Autifony Therapeutics Limited, Pangea Botanica and Perception Neurosciences. He serves as a Non-Executive Director at Heptares Therapeutics Limited. He began his career as a Faculty Member at the University of Michigan Medical School, where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters and book reviews. Dr. Pande had a distinguished academic career as a professor of psychiatry at the University of Michigan Medical School. He is an Author of more than 100 scientific publications and posters. Dr. Pande is a Psychiatrist and Fellow of several scientific societies, including the American Psychiatric Association. He had been Lead Independent Director of Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies Ltd.). since September 26, 2018 until April 2023 and as its Independent Director since March 2015 until April 2023. He serves on the Scientific Advisory Boards of Centrexion Corporation. Dr. Pande received his MBBS (Bachelor of Medicine, Bachelor of Surgery) and his M.D. from the University of Lucknow, India and completed his research fellowship training in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and psychiatry residency program at Western University.
Positions
- Company NameImmunovant, Inc.Stock CodeIMVTPositionIndependent Director
